Form 8-K - Current report:
SEC Accession No. 0001193125-24-283109
Filing Date
2024-12-20
Accepted
2024-12-20 16:07:00
Documents
14
Period of Report
2024-12-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d801773d8k.htm   iXBRL 8-K 26195
2 EX-99.1 d801773dex991.htm EX-99.1 146793
  Complete submission text file 0001193125-24-283109.txt   334978

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kura-20241216.xsd EX-101.SCH 2866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20241216_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20241216_pre.xml EX-101.PRE 11272
16 EXTRACTED XBRL INSTANCE DOCUMENT d801773d8k_htm.xml XML 3639
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 241567972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)